Onur BAYKARA, Nur BUYRU, Şadan SOYYİĞİT, Nuriye Banu TÖMEKÇE TAŞKIRAN

Türk popülasyonundaki koah hastalarında IL-1? polimorfizmi

Kronik obstrüktif akciğer hastalığı (KOAH) persistan hava akım kısıtlanması ile karakterize sık görülen bir hastalıktır. Çeşitli zararlı gaz ve partiküller hava yollarında kronik inflamasyona neden olurlar. İnterlökin-1 beta (IL-1?), makrofajlar, nötrofiller ve monositler gibi birçok hücre tarafından üretilen ana proinflamatuvar sitokindir ve proliferasyon, farklılaşma ve apoptoz gibi hücresel aktivitelerde görev alır. Daha önce yapılmış olan ve IL-1? ve KOAH arasındaki ilişkiyi inceleyen çalışmalarda çelişkili sonuçlar bulunmuştur. Bu çalışmanın amacı Türk popülasyonunda IL-1? -511 (rs 16944) ve +3954 (rs 1143634) gen polimorfizmleri ve KOAH arasındaki ilişkiyi incelemektir. hastalar ve Metod: Çalışmaya toplam 152 hasta dahil edilmiş ve üç gruba bölünmüştür; 72 KOAH hastası, 41 sigara içen sağlıklı birey ve 39 hiç sigara içmemiş sağlıklı birey. Polimeraz zincir reaksiyonu-restriksiyon parça uzunluk polimorfizmi (PZR-RFLP) yöntemi kullanılarak allel frekansları, genotip ve haplotip dağılımı belirlenmiştir.Bulgular: Genotip frekansları, haplotip ilişkisi, evre, cinsiyet veya sigara içme durumları açısından incelendiğinde gen polimorfizmleri ve KOAH arasında bir ilişki saptayamadık (p< 0.05). Sonuç: Sonuçlarımız KOAH ve IL-1?-511 ve +3954 gen polimorfizmleri arasında bir birliktelik olduğuna dair bir kanıt ortaya koymamaktadır.

IL-1? polymorphism in copd patients in Turkish population

Chronic obstructive pulmonary disease (COPD) is a common respiratory condition characterized by persistent airflow limitation and is associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Interleukin-1 beta (IL-1?) is a major pro-inflammatory cytokine expressed by many cells such as macrophages, neutrophils and monocytes and functions in cellular activities such as proliferation, differentiation and apoptosis. Recent studies demonstrate controversial results about the relationship between IL-1? and COPD. The aim of this study is to investigate the association between IL-1? -511 (rs 16944) and +3954 (rs 1143634) gene polymorphisms and COPD in Turkish population.patients and Methods: A total of 152 subjects were recruited in the study and divided into three groups: 72 COPD patients, 41 healthy smokers and 39 never-smokers. PCR-RFLP method was used to determine the allele frequencies, genotype and haplotype distributions. Results: We did not find any significant difference between the gene polymorphisms and COPD by means of genotype frequencies, haplotype association, stage, gender or smoking status (p< 0.05).conclusion: Our results do not show any evidence of association between COPD and IL-1? -511 and +3954 gene polymorphisms in Turkish population.

PDF

___

1. Pocket guide to COPD diagnosis, management and prevention. A guide for health care professionals. 2017 Report. Accession date:18 February 2017. Available from:http://goldcopd.org/pocket-guide-copd-diagnosismanagement-prevention-2016/
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
4. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD Study):a populationbased prevalence study. Lancet 2007;370:741-50.
5. Eisner MD, Anthonisen N, Coultas D, Kuenzli N, PerezPadilla R, Postma D, et al. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182:693-718.
6. Sandford AJ, Weir TD, Pare PD. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J 1997;10:1380-91.
7. Joos L, Pare PD, Sandford AJ. Genetic risk factors for chronic obstructive pulmonary disease. Swiss Med Wkly 2002;132:27-37.
8. Wu X, Yuan B, López E, Bai C, Wang X. Gene polymorphisms and chronic obstructive pulmonary disease. J Cell Mol Med 2014;18:15-26.
9. Nakamura H. Genetics of COPD. Allergol Int 2011;60:253-8.
10. Bal SM, Bernink JH, Nagasawa M, Groot J, Shikhagaie MM, Golebski K van Drunen CM, et al. IL-1?, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nat Immunol 2016;17:636-45.
11. Lomas DA, Silverman EK. The genetics of chronic obstructive pulmonary disease. Respir Res 2001;2:20-6.
12. Zinellu E, Zinellu A, Fois AG, Carru C, Pirina P. Circulating biomarkers of oxidative stress in chronic obstructive pulmonary disease: a systematic review. Respir Res 2016;17:150.
13. Hegab AE, Sakamoto T, Saitoh W, Nomura A, Ishii Y, Morishima Y, et al. Polymorphisms of TNF?, IL-1?, and IL-1RN genes in chronic obstructive pulmonary disease. Biochem Biophys Res Commun 2005;329:1246-52.
14. Joos L, McIntyre L, Ruan J, Connett JE, Anthonisen NR, Weir TD, et al. Association of IL-1? and IL-1 receptor antagonist haplotypes with rate of decline in lung function in smokers. Thorax 2001;65:863-6.
15. Shukla RK, Kant S, Bhattacharya S, Mittal B. Association of cytokine gene polymorphisms in patients with chronic obstructive pulmonary disease. Oman Med J 2012;27:285- 90.
16. Padrón-Morales J, Sanz C, Dávila I, Muñoz-Bellido F, Lorente F, Isidoro-García M. Polymorphisms of the IL12B, IL1B, and TNFA genes and susceptibility to asthma. J Investig Allergol Clin Immunol 2013;23:487-94.
17. Mahajan B, Vijayan VK, Agarwal MK, Bansal SK. Serum interleukin-1? as a marker for differentiation of asthma and chronic obstructive pulmonary disease. Biomarkers 2008;13:713-27.
18. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
19. DeMeo DL, Silverman EK. Genetics of chronic obstructive pulmonary disease. Semin Respir Crit Care 2003;24:151- 9.
20. Le J, Vilcek J. Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest 1987;56:234-48.
21. Ishii T, Matsuse T, Teramoto S, Matsui H, Miyao M, Hosoi T, et al. Neither IL-1?, IL-1 receptor antagonist, nor TNF? polymorphisms are associated with susceptibility to COPD. Respir Med 2000;94:847-51.
22. Lee JM, Kang YR, Park SH, Cha SI, Kim JS, Kang HK, et al. Polymorphisms in interleukin-1B and its receptor antagonist genes and the risk of chronic obstructive pulmonary disease in a Korean population: a case-control study. Respir Med 2008;102:1311-20.
23. Wang YS, Liu L, Xu XY, Wang JL, Zhou H, Li TL, et al. Association of interleukin-1? -511C/T promoter polymorphism with COPD risk: a meta-analysis. Genet Mol Res 2015;14:4477-84.
24. Xie ZK, Huang QP, Huang J, Xie ZF. Association between the IL1B, IL1RN polymorphisms and COPD risk: a metaanalysis. Sci Rep 2014;4:6202.
25. Eder C. Mechanisms of interleukin-1? release. Immunobiology 2009;214:543-53.
26. Sapey E, Ahmad A, Bayley D, Newbold P, Snell N, Rugman P, et al. Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD. J Clin Immunol 2009;29:508-16.
27. Pauwels NS, Bracke KR, Dupont LL, Van Pottelberge GR, Provoost S, VandenBerghe T, et al. Role of IL-1? and the Nlrp3/caspase-1/IL-1? axis in cigarette smoke-induced pulmonary inflammation and COPD. Eur Respir J 2011;38:1019-28.
28. Fu JJ, McDonald VM, Baines KJ, Gibson PG. Airway IL-1? and systemic inflammation as predictors of future exacerbation risk in asthma and COPD. Chest 2015;148:618-29.
29. Singh B, Arora S, Khanna V. Association of severity of COPD with IgE and interleukin-1 ?. Monaldi Arch Chest Dis 2010;73:86-7.
30. Guo Y, Jamison DC. The distribution of SNPs in human gene regulatory regions. BMC Genomics 2005;6:140.
31. Damera G, Pham TH, Zhang J, Ward CK, Newbold P, Ranade K, et al. A Sputum proteomic signature that associates with increased IL-1? levels and bacterial exacerbations of COPD. Lung 2016;194:363-9.